KalVista Pharmaceuticals Reports Material Agreement and Financials
Ticker: KALV · Form: 8-K · Filed: Feb 16, 2024 · CIK: 1348911
| Field | Detail |
|---|---|
| Company | Kalvista Pharmaceuticals, Inc. (KALV) |
| Form Type | 8-K |
| Filed Date | Feb 16, 2024 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.001, $15.25, $0, $150.1 m, $76 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financial-condition
TL;DR
**KalVista just dropped an 8-K about a new material agreement and financial updates, so keep an eye on their stock!**
AI Summary
KalVista Pharmaceuticals, Inc. filed an 8-K on February 16, 2024, reporting an event that occurred on February 14, 2024. The filing indicates an entry into a material definitive agreement and provides information on results of operations and financial condition. The company, based in Cambridge, MA, has a CIK of 0001348911 and is incorporated in Delaware.
Why It Matters
This filing signals a significant business development for KalVista Pharmaceuticals, potentially impacting its future operations and financial performance.
Risk Assessment
Risk Level: medium — The filing mentions a material definitive agreement and financial condition, but without specific details, the impact on the company's risk profile is unclear.
Key Players & Entities
- KalVista Pharmaceuticals, Inc. (company) — Registrant
- February 14, 2024 (date) — Date of earliest event reported
- February 16, 2024 (date) — Filing date
- 001-36830 (other) — Commission File Number
- Delaware (other) — State of Incorporation
FAQ
What was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on February 14, 2024.
When was this 8-K filed with the SEC?
This 8-K was filed with the SEC on February 16, 2024.
What is the full name of the registrant company?
The full name of the registrant company is KALVISTA PHARMACEUTICALS, INC.
What items of information were included in this 8-K filing?
The 8-K filing included information on Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Other Events, and Financial Statements and Exhibits.
What is the Commission File Number for KalVista Pharmaceuticals, Inc.?
The Commission File Number for KalVista Pharmaceuticals, Inc. is 001-36830.
Filing Stats: 1,429 words · 6 min read · ~5 pages · Grade level 12.1 · Accepted 2024-02-16 16:32:37
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 Par Value Per Share KALV The Nasdaq
- $15.25 — be sold at the public offering price of $15.25 per share. Pursuant to the Underwriting
- $0 — a Share is sold in the Offering, minus $0.001, and the exercise price of each Pre
- $150.1 m — from the Offering will be approximately $150.1 million, after deducting underwriting dis
- $76 million — marketable securities of approximately $76 million as of January 31, 2024. The prelimina
Filing Documents
- d729040d8k.htm (8-K) — 32KB
- d729040dex11.htm (EX-1.1) — 312KB
- d729040dex51.htm (EX-5.1) — 17KB
- d729040dex991.htm (EX-99.1) — 10KB
- g729040g0215144858892.jpg (GRAPHIC) — 4KB
- 0001193125-24-038522.txt ( ) — 594KB
- kalv-20240214.xsd (EX-101.SCH) — 3KB
- kalv-20240214_lab.xml (EX-101.LAB) — 18KB
- kalv-20240214_pre.xml (EX-101.PRE) — 11KB
- d729040d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description of Exhibit 1.1 Underwriting Agreement by and among KalVista Pharmaceuticals, Inc. and Jefferies LLC, Leerink Partners LLC, Stifel Nicolaus & Company, Incorporated, and Cantor Fitzgerald & Co., as representatives of the several underwriters, dated February 14, 2024. 5.1 Opinion of Fenwick & West LLP. 23.1 Consent of Fenwick & West LLP (contained in Exhibit 5.1). 99.1 Press Release relating to the pricing of the Offering, dated February 15, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein that do not describe historical facts, including, but not limited to, statements relating to the expected net proceeds of the Offering, the anticipated use of proceeds of the Offering and the timing of the closing of the Offering, are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. Such risks and uncertainties include, among others, the risks identified in the Company's filings with the SEC, including its Annual Report on Form 10-K for the year ended April 30, 2023, the prospectus supplements related to the Offering, and subsequent filings with the SEC. Any of these risks and uncertainties could materially and adversely affect the Company's results of operations, which would, in turn, have a significant and adverse impact on the Company's stock price. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made or to reflect the occurrence of unanticipated events. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KALVISTA PHARMACEUTICALS, INC. By: /s/ Benjamin L. Palleiko Benjamin L. Palleiko President, Chief Business Officer and Chief Financial Officer Date: February 16, 2024